 |
|
|
| |
INTERIM RESULTS OF A PHASE 1 STUDY OF RO7062931: A NOVEL LIVER-TARGETED SINGLE-STRANDED OLIGONUCLEOTIDE (SSO) WITH
LOCKED NUCLEIC ACID (LNA) THAT TARGETS HBV TRANSCRIPTS
|
| |
| |
AASLD 2019 Nov 8-12 Boston
Reported by Jules Levin
Edward J. Gane1, Cynthia Wat2, Sudip Das2, Bernadette Surujbally2, Christian Schwabe1, Katerina Glavini3, Miriam Triyatni3,
Vedran Pavlovic2, Henrik Mueller3, Simon Buatois3 and Joseph Grippo4
1Auckland Clinical Studies, Auckland, New Zealand; 2. Roche Innovation Centre, Welwyn Garden City, UK; 3. Roche Innovation Centre, Basel, Switzerland; 4. Roche Innovation Centre, New York, USA
|
| |
|
|
|
|
|
